奈帕芬胺0.3%用于糖尿病视网膜病变患者白内障术后:两项随机3期研究结果
两项前瞻性、随机、多中心、双盲、赋形剂对照3期研究分别纳入615例和605例糖尿病合并白内障手术患者,比较奈帕芬胺0.3%每日一次与赋形剂术后90天内黄斑水肿发生率及视力改善。奈帕芬胺0.3%组黄斑水肿发生率显著低于赋形剂组,合并分析显示视力改善更优,未观察到非预期不良事件。
要点
- 奈帕芬胺0.3%每日一次较赋形剂显著降低术后90天内黄斑水肿发生率(合并4.1% vs 15.9%,P<0.001)。
- 研究1中奈帕芬胺0.3%组第14天至第90天维持≥15字母视力改善比例高于赋形剂组(61.7% vs 43.0%,P<0.001),研究2无显著差异(48.8% vs 50.5%,P=0.671)。
- 两项研究均未观察到非预期不良事件。
核心结论
- 奈帕芬胺0.3%较赋形剂降低糖尿病视网膜病变患者白内障术后黄斑水肿风险,合并分析显示术后最佳矫正视力改善更优,且无未预期安全性事件。
研究设计与样本
- 两项前瞻性、随机、多中心、双盲、赋形剂对照3期研究,研究1纳入615例、研究2纳入605例患者,按1:1随机接受奈帕芬胺0.3%或赋形剂每日一次,自术前一天开始持续90天。
主要发现
- 术后90天内黄斑水肿(中央亚区黄斑厚度较术前基线增加≥30%)发生率:研究1奈帕芬胺0.3%组2.3% vs 赋形剂组17.3%(P<0.001);研究2 5.9% vs 14.3%(P=0.001);合并分析4.1% vs 15.9%(P<0.001)。
- 第14天至第90天维持≥15字母视力改善比例:研究1奈帕芬胺0.3%组61.7% vs 赋形剂组43.0%(P<0.001);研究2 48.8% vs 50.5%(P=0.671);合并分析55.4% vs 46.7%(P=0.003)。
- 术前至第90天≥15字母视力改善比例:研究1奈帕芬胺0.3%组77.2% vs 赋形剂组67.7%(P=0.009);研究2 65.4% vs 65.9%(P=0.888)。
- 术前至第60天≥15字母视力改善比例:研究1奈帕芬胺0.3%组76.2% vs 赋形剂组64.7%(P=0.002);研究2 68.9% vs 62.1%(P=0.092)。
- 两项研究均未观察到非预期不良事件。
关键数值与推荐
- 黄斑水肿定义为中央亚区黄斑厚度较术前基线增加≥30%。
- 主要视力终点为术前至第14天最佳矫正视力改善≥15字母且维持至第90天。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To demonstrate the efficacy and safety of once-daily nepafenac 0.3% ophthalmic suspension versus vehicle, based on clinical outcomes, after cataract surgery in patients with diabetes. DESIGN: Two prospective, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies. PARTICIPANTS: Total, 615 patients in study 1 and 605 patients in study 2. METHODS: Patients were randomized (1:1) to topical nepafenac 0.3% or vehicle once-daily starting the day before surgery and continuing for 90 days thereafter. MAIN OUTCOME MEASURES: Key efficacy variables were: patients (%) in whom macular edema (ME) developed (≥30% increase from preoperative baseline central subfield macular thickness) within 90 days after cataract surgery and the patients (%) with a best-corrected visual acuity (BCVA) improvement of ≥15 letters from preoperative baseline through day 14 maintained through day 90. Secondary end points included: patients (%) with a BCVA improvement of ≥15 letters from preoperative baseline through days 90 and 60 and safety over 3 months. RESULTS: A significantly lower percentage of patients demonstrated ME within 90 days after surgery with nepafenac 0.3% versus vehicle (study 1: 2.3% vs. 17.3%; P < 0.001; study 2: 5.9% vs. 14.3%; P = 0.001; pooled: 4.1% vs. 15.9%; P < 0.001). The percentage of patients achieving a ≥15-letter improvement from baseline through day 14 maintained through day 90 with nepafenac 0.3% versus vehicle was 61.7% versus 43.0% (P < 0.001) in study 1, 48.8% versus 50.5% (P = 0.671) in study 2, and 55.4% versus 46.7% (P = 0.003) in the pooled analysis. A greater percentage of patients treated with nepafenac 0.3% versus vehicle in study 1 and similar percentage in study 2 had a BCVA improvement of ≥15 letters from preoperative baseline through day 90 (77.2% vs. 67.7% [P = 0.009] and 65.4% vs. 65.9% [P = 0.888]) and through day 60 (76.2% vs. 64.7% [P = 0.002] and 68.9% vs. 62.1% [P = 0.092]). No unanticipated adverse events were observed. CONCLUSIONS: These studies demonstrated the clinical benefits of nepafenac 0.3% over vehicle in reducing the risk of postoperative ME, with the integrated analysis showing improved BCVA after cataract surgery in patients with diabetic retinopathy, with no unanticipated safety events.
引用
- Singh RP, Lehmann R, Martel J, et al. Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies. Ophthalmology. 2017. PMID: 28268098. doi:10.1016/j.ophtha.2017.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。